LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.04
−2.34%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 9813.79x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 1.16x
- Price / sales
- —
- Price / cash flow
- -2.03x
Enterprise value
- Enterprise value
- $103.4M
- EV / sales
- 3828.47x
- EV / EBITDA
- -0.43x
- EV / EBIT
- -0.54x
- Market cap
- $270.5M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026